|
|
|
|
Microsoft PowerPoint - 08_Riva_Print.ppt
1 Novartis Oncology Pipeline Broad and Deep Portfolio Alessandro Riva Senior VP, Head of Development 2 London Pharmaceutical Pipeline Event 2005 / Alessandro Riva Agenda ° Portfolio overview and late stage project highlights ° Mid to early stage oncology pipeline update ° Summary and conclusions 2 3 London Pharmaceutical Pipeline Event 2005 / Alessandro Riva Broad...
author: MEETIPL1
duplicates:
http://www.novartis.com/downloads/08_Riva_Print_london.pdf
http://www.novartis.com/downloads_new/investors/08_Riva_Print_london.pdf
http://www.novartis.com/downloads/08_Riva_Print_london.pdf
|
|
|
BioPortfolio Limited
Aromatase Inhibitors in Breast Cancer State of the Science and Strategic Opportunities Table of Contents I.
Executive Briefing II.
State of the Science A.
Introduction B.
The Genetics of Breast Cancer C.
Strategies for the Detection of Breast Cancer E.
Treatment Strategies 1.
Chemotherapy 3.
Breast Cancer Prevention F.
Aromatase Inhibitors Vs Hormone...
|
|
|
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
1 Novartis Oncology and Specialty Medicines David R.
BMS354825 Different Approaches to Treating CML · AMN107: the most selective BCR- ABL inhibitor reported to date · We believe this selectivity will confer best- in- class tolerability critical for a long- term therapy in CML AMN107 BMS354825 Pre- clinical activity against most BCR- ABL mutants Activity against T315I...
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20%20Analysts_Corrected_27_01_2005.pdf
cancer, chemotherapy, corticosteroids, poor oral hygiene) · December 2004 – addition of a warning that pre- existing renal insufficiency and multiple cycles of Zometa ® and other bisphosphonates are risk factors for subsequent renal deterioration with Zometa ® Dose reductions are recommended based on patient's creatinine clearance levels · Letters sent to...
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
400, ERYTHROMYCIN ETHYLSUCCINATE E.E.S., ERYTHROMYCIN ETHYLSUCCINATE EC-NAPROSYN, NAPROXEN ECONAZOLE NITRATE, ECONAZOLE NITRATE ECONOCHLOR, CHLORAMPHENICOL ECONOPRED PLUS, PREDNISOLONE ACETATE ECONOPRED, PREDNISOLONE ACETATE EDECRIN, ETHACRYNATE SODIUM EDECRIN, ETHACRYNIC ACID EDETATE DISODIUM, EDETATE DISODIUM EDEX, ALPROSTADIL EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM...
|
|
|
20-726S006_Femara.htm
Food and Drug Administration • Center for Drug Evaluation and Research Approval Package Search Femara (Letrozole) Tablets Company:- Novartis Pharmaceuticals Corp
Application No.:- 20-726/S006 Approval Date:-1/10/2001 - Approval Letter(s) - Printed Labeling - Medical Review(s)- Part 1 - Part 2 - Chemistry Review(s) - Statistical Review(s) Part 1 - Part 2 Clinical...
author: Paul Stauffer
|
|
|
CDER Report to the Nation: 2001
Food and Drug Administration • Center for Drug Evaluation and Research About CDER - Report Search CDER Report to the Nation: 2001 Table of Contents 1 Drug Review Index Mission Highlights New Drug Review Standard new drugs Priority new drugs New molecular entities Standard NMEs Priority NMEs Orphan drug approvals Notable 2001 new drug approvals New or Expanded Use Review...
author: OLIVERN
|
|
|
News Along the Pike, January 2001
Food and Drug Administration • Center for Drug Evaluation and Research About CDER Search CDER News Along the Pike January 2001 Volume 6, Issue 12 Center for Drug Evaluation and Research PDF version for printouts
Of necessity, these decisions are often made with less information than we would like, because if we waited for all the desired data, bodies would start to pile up...
author: Oliver
|
|
|
InvestBio Report Volume II, No. 1 page 4
author: Diversified Biotech Group, Inc.
subject: InvestBio Report
|
|
|
APPROVED LABELING NDA 20-726/S-006
It is chemically described as 4,4'-(1H- and its structural formula is Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to...
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 15
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 14
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 13
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 12
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 11
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 10
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 9
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 8
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 7
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 6
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 5
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 4
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 3
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 2
author: JFG
subject: femara (letrozole tablets)
|
|
|
APPROVED LABELING NDA 20-726/S-006 page 1
author: JFG
subject: femara (letrozole tablets)
|
